House dust mite allergy vaccine - Novozymes

Drug Profile

House dust mite allergy vaccine - Novozymes

Alternative Names: Allergy vaccine - Novozymes

Latest Information Update: 08 Nov 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novozymes A/S
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypersensitivity

Most Recent Events

  • 07 Nov 2005 Discontinued - Preclinical for Allergy in Denmark (unspecified route)
  • 02 Jun 2005 The house dust mite allergy vaccine has been outlicensed
  • 08 Jun 2004 Preclinical trials in Allergy in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top